

PHARMACY POLICY – 5.01.615


Pharmacologic Treatment of Chronic Non-Infectious Liver Diseases

Effective Date: Feb. 1, 2025
Last Revised: Jan. 14, 2025
Replaces: N/A

RELATED MEDICAL POLICIES:
None

Select a hyperlink below to be directed to that section.

[POLICY CRITERIA](#) | [DOCUMENTATION REQUIREMENTS](#) | [CODING](#)
[RELATED INFORMATION](#) | [EVIDENCE REVIEW](#) | [REFERENCES](#) | [HISTORY](#)

 Clicking this icon returns you to the hyperlinks menu above.

Introduction

Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease. The body's immune system mistakenly attacks the liver's healthy cells in the small bile ducts (intrahepatic bile ducts). Bile is a fluid made by the liver. It removes toxins and waste from the body and helps with digestion. In PBC, the bile ducts become damaged and destroyed over time. Bile then builds up and causes scarring of the liver (cirrhosis). Treatment of PBC is meant to slow down the progression of liver damage. Metabolic dysfunction–associated steatotic liver disease (MASLD) is a common chronic liver condition and is often associated with obesity and type 2 diabetes. It is estimated that about 25% of the US population is affected by MASLD, although many people do not know that they have it. Metabolic dysfunction–associated steatohepatitis (MASH) is the most severe form of MASLD and is characterized by an accumulation of fat in the liver. People with MASH are more likely to develop serious liver complications such as liver failure or liver cancer. This policy describes when drugs used to treat chronic non-infectious liver diseases may be considered medically necessary.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

Policy Coverage Criteria

Drug	Medical Necessity
Primary Biliary Cholangitis	
Iqirvo (elafibranor) (oral)	<p>Iqirvo (elafibranor) may be considered medically necessary for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA when the following criteria are met:</p> <ul style="list-style-type: none"> • The individual is aged 18 years or older <p>AND</p> <ul style="list-style-type: none"> • Has PBC without cirrhosis <p>OR</p> <ul style="list-style-type: none"> • Has PBC with compensated cirrhosis (Child-Pugh A) and no evidence of portal hypertension <p>AND</p> <ul style="list-style-type: none"> • Diagnosis is confirmed by consistently elevated alkaline phosphatase (ALP) for at least 6 months at time of diagnosis and one of the following: <ul style="list-style-type: none"> ○ Positive antimitochondrial (AMA) test <p>OR</p> <ul style="list-style-type: none"> • Presence of sp100 or gp210 autoantibodies if AMA negative <p>OR</p> <ul style="list-style-type: none"> • Liver biopsy consistent with PBC <p>AND</p> <ul style="list-style-type: none"> • The diagnosis is not associated with a cholestatic drug reaction, complete biliary obstruction, sarcoidosis, and primary sclerosing cholangitis <p>AND</p> <ul style="list-style-type: none"> • The individual has tried ursodeoxycholic acid (UDCA) for at least 1 year and had an inadequate response to UDCA therapy <p>OR</p> <ul style="list-style-type: none"> • The individual has tried UDCA and has a documented intolerance to use of UDCA <p>AND</p>

Drug	Medical Necessity
Primary Biliary Cholangitis	
	<ul style="list-style-type: none"> • Iqirvo (elafibranor) is prescribed by or in consultation with a gastroenterologist or hepatologist <p>AND</p> <ul style="list-style-type: none"> • Iqirvo (elafibranor) will not be used in combination with Livdelzi (seladelpar) or Ocaliva (obeticholic acid) <p>AND</p> <ul style="list-style-type: none"> • The dose is limited to 80 mg once daily <p>Note: See Documentation Requirements prior to request for approval.</p>
Livdelzi (seladelpar) (oral)	<p>Livdelzi (seladelpar) may be considered medically necessary for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA when the following criteria are met:</p> <ul style="list-style-type: none"> • The individual is aged 18 years or older <p>AND</p> <ul style="list-style-type: none"> • Has PBC without cirrhosis <p>OR</p> <ul style="list-style-type: none"> • Has PBC with compensated cirrhosis (Child-Pugh A) and no evidence of portal hypertension <p>AND</p> <ul style="list-style-type: none"> • Diagnosis is confirmed by consistently elevated alkaline phosphatase (ALP) for at least 6 months at time of diagnosis and one of the following: <ul style="list-style-type: none"> ○ Positive antimitochondrial (AMA) test <p>OR</p> <ul style="list-style-type: none"> • Presence of sp100 or gp210 autoantibodies if AMA negative <p>OR</p> <ul style="list-style-type: none"> • Liver biopsy consistent with PBC <p>AND</p> <ul style="list-style-type: none"> • The diagnosis is not associated with a cholestatic drug reaction, complete biliary obstruction, sarcoidosis, and primary sclerosing cholangitis <p>AND</p>

Drug	Medical Necessity
Primary Biliary Cholangitis	
	<ul style="list-style-type: none"> The individual has tried ursodeoxycholic acid (UDCA) for at least 1 year and had an inadequate response to UDCA therapy OR the individual has tried UDCA and has a documented intolerance to use of UDCA <p>AND</p> <ul style="list-style-type: none"> Livdelzi (seladelpar) is prescribed by or in consultation with a gastroenterologist or hepatologist <p>AND</p> <ul style="list-style-type: none"> Livdelzi (seladelpar) will not be used in combination with Iqirvo (elafibranor) or Ocaliva (obeticholic acid) <p>AND</p> <ul style="list-style-type: none"> The dose is limited to 10 mg once daily <p>Note: See Documentation Requirements prior to request for approval.</p>
Ocaliva (obeticholic acid) (oral)	<p>Ocaliva (obeticholic acid) may be considered medically necessary for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA when the following criteria are met:</p> <ul style="list-style-type: none"> The individual is aged 18 years or older <p>AND</p> <ul style="list-style-type: none"> Has PBC without cirrhosis <p>OR</p> <ul style="list-style-type: none"> Has PBC with compensated cirrhosis (Child-Pugh A) and no evidence of portal hypertension <p>AND</p> <ul style="list-style-type: none"> Diagnosis is confirmed by consistently elevated alkaline phosphatase (ALP) for at least 6 months at time of diagnosis and one of the following: <ul style="list-style-type: none"> Positive antimitochondrial (AMA) test <p>OR</p> <ul style="list-style-type: none"> Presence of sp100 or gp210 autoantibodies if AMA negative <p>OR</p>

Drug	Medical Necessity
Primary Biliary Cholangitis	
	<ul style="list-style-type: none"> ○ Liver biopsy consistent with PBC <p>AND</p> <ul style="list-style-type: none"> • The diagnosis is not associated with a cholestatic drug reaction, complete biliary obstruction, sarcoidosis, and primary sclerosing cholangitis <p>AND</p> <ul style="list-style-type: none"> • The individual has tried UDCA for at least 1 year and had an inadequate response to UDCA therapy OR the individual has tried UDCA and has a documented intolerance to use of UDCA <p>AND</p> <ul style="list-style-type: none"> • Ocaliva (obeticholic acid) is prescribed by or in consultation with a gastroenterologist or hepatologist <p>AND</p> <ul style="list-style-type: none"> • Ocaliva (obeticholic acid) will not be used in combination with Iqirvo (elafibranor) or Livdelzi (seladelpar) <p>AND</p> <ul style="list-style-type: none"> • The dose is limited to 10 mg once daily <p>Note: See Documentation Requirements prior to request for approval.</p>
Rezdiffra (resmetirom) (oral)	<p>Rezdiffra (resmetirom) may be considered medically necessary for the treatment of stage F2 or F3 liver fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH) when ALL the following criteria are met:</p> <ul style="list-style-type: none"> • The individual is aged 18 years or older <p>AND</p> <ul style="list-style-type: none"> • Has evidence of hepatic steatohepatitis and stage F2 or F3 fibrosis confirmed by a liver biopsy or a liver test <p>AND</p> <ul style="list-style-type: none"> • Meets ALL the following <ul style="list-style-type: none"> ○ Consuming less than or equal to 15 standard drinks per week if male or less than or equal to 10 standard drinks per week if female ○ Negative or undetectable hepatitis C viral load OR a suppressed hepatitis C viral load for 12 weeks prior to starting Rezdiffra (resmetirom)

Drug	Medical Necessity
Primary Biliary Cholangitis	
	<ul style="list-style-type: none"> Does not have a diagnosis of hemochromatosis as defined by a serum transferrin saturation of greater than or equal to 45% and a serum ferritin above the normal range If the individual is less than 30 years of age, the individual does not have a diagnosis of Wilson's disease If the individual has a diagnosis of type 2 diabetes mellitus, the individual has an A1c less than 9% If the individual has a body mass index greater or equal to 30, the individual is following diet modification using a dietary plan and has increased physical activity using a fitness plan Does not have cirrhosis (F4 fibrosis) <p>AND</p> <ul style="list-style-type: none"> Has tried maximum tolerated doses of atorvastatin OR rosuvastatin for greater or equal to 8 continuous weeks unless not tolerated or contraindicated <p>AND</p> <ul style="list-style-type: none"> Will be treated with a statin while receiving Rezdiffra (resmetirom) unless not tolerated or contraindicated <p>AND</p> <ul style="list-style-type: none"> Rezdiffra (resmetirom) will not be used in combination with obeticholic acid <p>AND</p> <ul style="list-style-type: none"> Rezdiffra (resmetirom) is prescribed by or in consultation with a gastroenterologist or hepatologist <p>AND</p> <ul style="list-style-type: none"> Dose is limited to 100 mg daily

Drug	Investigational
<ul style="list-style-type: none"> Iqirvo (elafibranor) Livdelzi (seladelpar) Ocaliva (obeticholic acid) Rezdiffra (resmetirom) 	<p>All other uses of Iqirvo, Livdelzi, Ocaliva, and Rezdiffra for conditions not outlined in this policy are considered investigational.</p>

Drug	Investigational
	The medications listed in this policy are subject to the product's US Food and Drug Administration (FDA) dosage and administration prescribing information.

Length of Approval	
Approval	Criteria
Initial authorization	<p>Non-formulary exception reviews for all drugs listed in the policy may be approved up to 12 months.</p> <p>All other reviews for Iqirvo, Livdelzi, and Ocaliva may be approved up to 6 months.</p> <p>All other reviews for Rezdiffra may be approved up to 12 months.</p>
Re-authorization criteria	<p>Non-formulary exception reviews and all other reviews for Iqirvo, Livdelzi, and Ocaliva may be approved up to 12 months as long as the drug-specific coverage criteria are met, and chart notes demonstrate that the individual continues to show a reduced alkaline phosphatase (ALP) level from baseline.</p> <p>Non-formulary exception reviews and all other reviews for Rezdiffra may be approved up to 12 months as long as the drug-specific coverage criteria are met, and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.</p>

Documentation Requirements
<p>The individual's medical records submitted for review for all conditions should document that medical necessity criteria are met. The record should include the following:</p> <ul style="list-style-type: none"> Office visit notes that contain the diagnosis, relevant history, physical evaluation and medication history

Coding

N/A

Related Information

Benefit Application

The drugs in this policy are managed through the pharmacy benefit.

Evidence Review

Primary Biliary Cholangitis (PBC)

Primary Biliary Cholangitis, or PBC, is considered an autoimmune disease because of its hallmark serologic signature, antimitochondrial antibody (AMA), and specific bile duct pathology. PBC is a chronic cholestatic disease with a progressive course that may extend over many decades. The major symptoms of PBC are fatigue and itching and there is not a good correlation between these symptoms and stage of disease, although individuals with more advanced disease generally have more symptoms. Data suggests that PBC has a higher prevalence in women than men.

Alkaline Phosphatase (ALP)

Alkaline phosphatase is an enzyme found throughout the body, but is mostly found in the liver, bones, kidneys, and digestive system. When the liver is damaged, ALP may leak into the bloodstream.

Obeticholic Acid (OCA)

Ocaliva (obeticholic acid, OCA) is a farnesoid X receptor (FXR) agonist indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults without cirrhosis or with compensated cirrhosis who do not have evidence of portal



hypertension, with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. This indication was approved under accelerated approval based on a reduction in alkaline phosphatase (ALP). An improvement in survival or disease-related symptoms has not been established.

The efficacy and safety of OCA in individuals with PBC was evaluated in a 12-month, double-blind, placebo-controlled, Phase III trial (POISE). Participants who had an inadequate response to ursodiol (UDCA) were randomized in a 1:1:1 ratio to receive obeticholic acid (10 mg and 5-10 mg) and placebo. Criteria for inclusion included definite or probable PBC diagnosis, $ALP \geq 1.67$ of upper limit of normal (ULN) or total bilirubin $> ULN$, trial and failure of UDCA for at least 12 months or intolerability to UDCA. The primary composite endpoint of the study was an ALP level of less than 1.67 times the upper limit of the normal range, with a reduction of at least 15% from baseline and a total bilirubin level at or below the upper limit of the normal range at 12 months.

Ursodeoxycholic Acid (UDCA)

Ursodeoxycholic acid or UDCA was the first drug approved for the treatment of individuals with PBC in the United States. Several randomized trials, combined analyses and long-term observational studies have shown that UDCA not only improves biochemical indices but also delays histologic progression and improves survival without transplantation. UDCA is the initial drug of choice for PBC therapy.

Summary of Evidence

Ocaliva (obeticholic acid)

Trials in Primary Biliary Cholangitis

The safety and efficacy of obeticholic acid (OCA) for the treatment of individuals with primary biliary cholangitis who have not achieved treatment goal with UDCA alone or cannot tolerate UDCA was established in a placebo-controlled 12-month double-blind randomized-controlled study. Individuals with alkaline phosphatase level of at least 1.67 times the upper limit of normal or an abnormal total bilirubin level of <2 times the upper limit of normal were included in the study. Individuals were randomly assigned 1:1:1 ratio to receive once-daily oral placebo ($n=73$), OCA 5-10mg dose ($n=70$) and obeticholic acid 10 mg ($n=73$) to be added to ursodiol. Majority of the participants in the study were female (90%) with a mean alkaline phosphatase value of 323 U/L and mean total bilirubin of 0.65 mg/dl. The primary endpoint of the study was an

alkaline phosphatase level of <1.67 times the upper limit of normal with a reduction of $\geq 15\%$ from baseline, and a total bilirubin level at or below upper limit of the normal range at 12 months.

On a background of standard of care, the rate of the primary end point was higher in the 5–10-mg group (46%) and in the 10-mg group (47%) than in the placebo group (10%) at month 12 ($P < 0.001$ for both comparisons). Response to obeticholic acid was rapid, with a significant difference observed between each obeticholic acid group and the placebo group by week 2 and at each time point thereafter in the double-blind phase ($P < 0.001$ for all comparisons).

A total of 193 of 198 individuals (97%) who completed the 12-month double-blind randomized-controlled study were enrolled in the open-label extension study to evaluate sustained reductions in alkaline phosphatase levels and total bilirubin levels. This extension showed a durable response with obeticholic acid for 2 years. Individuals in the placebo arm who were initiated on obeticholic acid in the open-label extension had similar efficacy to those who were started on obeticholic acid during the double-blind phase.

During the double-blind phase, 19 individuals withdrew from the study, 1 individual (1%) died (from an exacerbation of preexisting congestive heart failure and ischemic heart disease as determined by hospital staff), 8 individuals (4%) withdrew because of pruritus, 6 (3%) withdrew because of other adverse events, and 4 (2%) withdrew consent. The most common adverse event that occurred during the double-blind phase across all groups, including placebo, was pruritus, with an incidence reported in 56% of participants in the 5–10 mg group, 68% in 10 mg group and in 38% in the placebo group. High-density lipoprotein (HDL) cholesterol levels decreased in individuals in the two obeticholic acid groups but stabilized within the normal range and were similar to levels observed in individuals in the placebo group after 12 months. At week 2, a sustained decrease from baseline in the triglyceride level and an increase from baseline in the level of low-density lipoprotein (LDL) cholesterol were observed, as compared with the changes from baseline with placebo.

Iqirvo (elafibranor)

In the Phase 3 ELATIVE trial (NCT04526665), the composite primary endpoint of biochemical response (alkaline phosphatase [ALP] <1.67 times upper limit of normal [ULN], total bilirubin [TB] \leq ULN, and ALP decreases $\geq 15\%$ from baseline) was achieved in 51% of individuals treated with Iqirvo (with or without UDCA) versus 4% of patients who received placebo (with or without UDCA), for a 47% treatment difference. Secondary endpoints showed normalization in ALP levels in only Iqirvo-treated individuals (15% for Iqirvo with or without UDCA versus 0% for placebo

with or without UDCA). Most individuals (95%) received study treatment (Iqirvo or placebo) in combination with UDCA. Iqirvo received accelerated approval based on the surrogate endpoint of reduction in ALP, which the FDA believed could be relied on as reasonably likely to predict clinical benefit, including an improvement in transplant-free survival. As with all FDA accelerated approvals, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). For Iqirvo, confirmation of clinical benefit will be evaluated in the ongoing Phase 3 ELFIDENCE study (NCT06016842). The most common adverse reactions with Iqirvo reported in $\geq 10\%$ of study participants were weight gain, abdominal pain, diarrhea, nausea and vomiting. The label for Iqirvo includes warnings regarding myalgia, myopathy, and rhabdomyolysis; fractures; adverse effects on fetal and newborn development; drug-induced liver injury; hypersensitivity reactions; and biliary obstruction. Iqirvo is not recommended for people who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, and hepatic encephalopathy).

Livdelzi (seladelpar)

Seladelpar was studied in two Phase 3 trials and a trial extension, two of which were terminated early due to histological results in a Phase 2 NASH trial. As the histological results were determined to predate exposure to seladelpar by an independent review committee, the final Phase 3 trial (RESPONSE) was conducted in its entirety.

The RESPONSE trial was a well-designed Phase 3 trial which randomized 193 patients to seladelpar 10 mg once daily or placebo for 12 months. Patients were adults with PBC with an incomplete response to UDCA or intolerance to UDCA. All patients who were able to tolerate UDCA continued UDCA throughout the study. Patients with advanced PBC or hepatic decompensation were excluded. The primary endpoint of biochemical response per POISE criteria was met in 61.7% of patients on seladelpar and 20% on placebo (difference 41.7 percentage points, 95% CI 27.7-53.4; $p < 0.001$). Results were consistent in patients with cirrhosis vs no cirrhosis, and with seladelpar monotherapy vs UDCA + seladelpar. Normalization of ALP at 12 months occurred in 25% of patients on seladelpar and 0% on placebo ($p < 0.001$). Pruritus as assessed via numerical rating scale (NRS) at 6 months in patients with moderate-severe pruritus at baseline was significantly reduced with seladelpar vs placebo ($p = 0.005$). Total cholesterol, low-density lipoprotein (LDL), and triglycerides decreased with seladelpar while HDL increased.

The ENHANCE trial was a well-designed Phase 3 trial originally designed with a 12-month duration. The trial was terminated early due to histological results in a Phase 2 seladelpar trial in patients with NASH. Only 3-month trial results are available. The trial randomized patients to

seladelpar 5 mg, 10mg, or placebo. See the RESPONSE trial for inclusion/exclusion criteria. The primary endpoint of biochemical response per POISE criteria occurred significantly more frequently in patients in the seladelpar arms vs placebo (78.2%, 57.1%, 12.5%, $p < 0.001$ for both comparisons). Significantly less pruritus as assessed by numerical rating scale (NRS) and significantly greater alkaline phosphatase (ALP) normalization occurred in the seladelpar arms vs placebo. However, because the trial was terminated early, the trial was underpowered with only 167 patients of 265 patients able to provide 3 months data.

Similarly, Mayo published an open-label trial extension which was terminated early due to the Phase 2 NASH results mentioned above. The trial extension enrolled 106 patients who completed seladelpar trials (Phase 2 trial and the ENHANCE trial) and were treated with seladelpar 2-10 mg once daily for up to 2 years. The trial extension found patients achieving the biochemical response endpoint increased from year 1 to year 2 (year 1: 63%-66%; year 2: 79%). Normalization of ALP followed the same pattern (year 1: 23%-26%, year 2: 42%). Of note, baseline characteristics between seladelpar dosing arms were not balanced in this trial.

The label for Livdelzi includes warnings for fractures, liver test abnormalities, and biliary obstruction. The most common adverse reactions (reported in $\geq 5\%$ and higher compared to placebo) are headache, abdominal pain, nausea, abdominal distension, and dizziness.

Metabolic Dysfunction–Associated Steatohepatitis (MASH)

Metabolic dysfunction–associated steatotic liver disease (MASLD) is common in the general population. An estimated 25% of adults in the United States (US) have MASLD. MASLD requires the presence of fat in the liver (hepatic steatosis [HS]) without another explanation such as significant alcohol consumption or use of medications that cause HS. Metabolic dysfunction–associated steatohepatitis (MASH) occurs in which HS is accompanied by hepatocellular injury.

The exact prevalence of MASH is uncertain since definitive diagnosis requires liver biopsy, and many patients with MASLD do not undergo biopsy. It is estimated that the prevalence of MASH in the adult population is between 1.5% and 6.5%. Patients with MASH may have liver fibrosis, and liver fibrosis can progress to cirrhosis. Patients with cirrhosis are at high risk of death from liver failure and liver cancer (hepatocellular carcinoma [HCC]) and may require liver transplantation. MASLD is highly associated with the metabolic syndrome with or without type 2 diabetes mellitus (T2DM) and obesity. Metabolic syndrome has a number of different definitions, but a commonly used one is at least three of: increased waist circumference; elevated triglyceride level; reduced high density lipoprotein (HDL) cholesterol level; elevated blood pressure; and elevated blood glucose (blood sugar). Metabolic syndrome is a major risk factor for cardiovascular disease (CVD), and despite an increased risk of death from liver-related



causes, CVD is the most common cause of death in patients with MASLD. Statins appear to improve CV outcomes in patients with MASH. MASH has become a major cause of cirrhosis and is expected to become the leading reason for liver transplantation in the US. Lifestyle changes that result in improvement in metabolic syndrome, including exercise and weight loss, can improve MASH, as can weight loss after bariatric surgery; bariatric surgery also improves T2DM and the metabolic syndrome. Resmetirom is now the first FDA-approved treatment for MASH and was FDA-approved on March 14, 2024.

Rezdiffra (resmetirom)

The efficacy of resmetirom was evaluated based on an efficacy analysis at Month 12 in Trial 1 (NCT03900429), a 54-month, randomized, double-blind, placebo-controlled trial. Enrolled patients had metabolic risk factors and a baseline or recent liver biopsy showing metabolic dysfunction–associated steatohepatitis (MASH) with fibrosis stage 2 or 3 and a metabolic dysfunction–associated steatotic liver disease (MASLD) Activity Score (MAS) of at least 4. Efficacy determination was based on the effect of resmetirom on resolution of steatohepatitis without worsening of fibrosis and one stage improvement in fibrosis without worsening of steatohepatitis, on post-baseline liver biopsies collected at 12 months.

The month 12 analysis included 888 F2 and F3 (at eligibility) patients randomized 1:1:1 to receive placebo (n = 294), resmetirom 80 mg once daily (n = 298), or resmetirom 100 mg once daily (n = 296), in addition to lifestyle counseling on nutrition and exercise. Patients were on stable doses of medications for diabetes, dyslipidemia, and hypertension.

Efficacy results were based on the percentage of patients meeting clinical endpoints based on biopsy readings performed by two pathologists (Pathologist A and Pathologist B). Results for the MASH resolution endpoint based on Pathologist A's readings were 27%, 36%, and 13% for resmetirom 80 mg, resmetirom 100 mg, and placebo, respectively. For the same endpoint, results based on Pathologist B's readings were 26%, 24%, and 9% for resmetirom 80 mg, Rezdiffra 100 mg, and placebo, respectively. Results for the fibrosis endpoint based on Pathologist A's readings were 23%, 28%, and 15% for resmetirom 80 mg, resmetirom 100 mg, and placebo, respectively. For the same endpoint, results based on Pathologist B's readings were 23%, 24%, and 13% for resmetirom 80 mg, resmetirom 100 mg, and placebo, respectively. Examination of age, gender, diabetes status (Yes or No), and fibrosis stage (F2 or F3) subgroups did not identify differences in response to resmetirom among these subgroups.



The most common adverse reactions with resmetirom (reported in $\geq 5\%$ of patients and at a higher rate than placebo) are diarrhea, nausea, pruritus, vomiting, constipation, abdominal pain, and dizziness.

Practice Guidelines and Position Statements

2018 Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (AASLD)

Diagnosis of PBC

According to the AASLD guidelines, the diagnosis of PBC can be established when 2 of the following criteria are met:

- Biochemical evidence of cholestasis based on ALP elevation.
- Presence of AMA, or other PBC-specific autoantibodies, including sp100 or gp210, if AMA is negative.
- Histologic evidence of nonsuppurative destructive cholangitis and destruction of interlobular bile ducts

Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases (AASLD)

The 2018 Practice Guidance was updated to reflect the warning issued by the Food and Drug Administration in May 2021 restricting the use of OCA in individuals with advanced cirrhosis. AASLD recommends careful monitoring of any individual receiving obeticholic acid with any cirrhosis, even if not advanced. AASLD also revised guidelines to include fibrates as a potential off-label alternative for individuals with PBC and inadequate response to UDCA.

Treatment of PBC

The first-line therapy for PBC is UDCA (ursodeoxycholic acid) or ursodiol dosed at 13 to 15 mg/kg/day. UDCA is widely used and has demonstrated the ability to produce a reduction in need for liver transplantation for individuals with PBC. Treatment response to UDCA is



monitored using serum ALP and total bilirubin. Improvement in these tests are typically observed within a few weeks, and 90% of improvement occurs within 6 to 9 months. The guidelines recommend that biochemical response to UDCA be evaluated at 12 months after treatment initiation to determine whether individuals should be considered for second-line therapy.

The second-line therapy recommended by AASLD (2018) for PBC is obeticholic acid. Individuals who are inadequate responders to UDCA should be considered for treatment with OCA (starting dose 5 mg per day).

Fibrates can be considered as an off-label alternative for individuals who have an inadequate response to UDCA according to AASLD (2021). The use of fibrates has not been studied in individuals with decompensated liver disease and should be avoided in this population. Therefore, long-term safety of fibrates in individuals with PBC warrants additional studies.

2021 Update

Reviewed prescribing information for Ocaliva (obeticholic acid). Prescribing information now includes a black box warning describing that hepatic decompensation and failure, sometimes fatal or resulting in liver transplant, have been reported with Ocaliva and that Ocaliva is contraindicated in primary biliary cholangitis (PBC) patients with decompensated cirrhosis, a prior decompensation event, or with compensated cirrhosis who have evidence of portal hypertension. The indication for Ocaliva has been updated to restrict use to individuals without cirrhosis or with compensated cirrhosis who do not have evidence of portal hypertension.

2022 Update

Reviewed prescribing information for Ocaliva (obeticholic acid). Reviewed 2021 practice guidance update from the American Association for the Study of Liver Diseases (AASLD). No new information was identified that would result in a change to the policy coverage criteria.

2023 Update

Reviewed prescribing information for Ocaliva (obeticholic acid). No new information was identified that would result in a change to the policy coverage criteria.



2024 Update

Reviewed prescribing information for Ocaliva (obeticholic acid). Added Iqirvo (elafibranor) coverage criteria. Updated Ocaliva (obeticholic acid) coverage criteria to include a prescriber requirement, a requirement that Ocaliva will not be used in combination with Iqirvo, and a quantity limit.

2025 Update

Reviewed prescribing information for Ocaliva (obeticholic acid), Iqirvo (elafibranor), and Rezdiffra (resmetirom). No new information was identified that would result in a change to the policy coverage criteria. Added Livdelzi (seladelpar) coverage criteria for the treatment of PBC. Updated Iqirvo and Ocaliva criteria to exclude combination use with Livdelzi. Rezdiffra (resmetirom) moved from Policy 5.01.605 to Policy 5.01.615 Pharmacologic Treatment of Chronic Non-Infectious Liver Diseases with no changes to the coverage criteria. Clarified that the medications listed in this policy are subject to the product's FDA dosage and administration prescribing information. Clarified that non-formulary exception review authorizations for all drugs listed in this policy may be approved up to 12 months.

References

1. Ocaliva (obeticholic acid) prescribing information. Intercept Pharmaceuticals, Inc. New York, NY. Revised May 2022.
2. Lindor KD, Bolus CL, Boyer J, et al. Primary biliary cholangitis: 2018 Practice guidance from the American Association for the Study of Liver Disease. *Hepatology*. 2019. 69(1):394-419. doi: 10.1002/hep.30145.
3. Alkaline Phosphatase. Medline Plus. Updated November 5, 2024. Available at: <https://medlineplus.gov/lab-tests/alkaline-phosphatase/> Accessed January 7, 2025.
4. Siddique A, Kowdley KV. Approach to a patient with elevated serum alkaline phosphatase. *Clin Liver Dis*. 2012 May; 16(2): 199–229.
5. Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. *N Engl J Med*. 2016;375:631-43.
6. Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Disease. *Hepatology*. 2021. 75:1012-1013. doi: 10.1002/hep.32117.



7. Iqirvo (elafibranor) prescribing information. Ipsen Biopharmaceuticals, Inc. Cambridge, MA. Revised June 2024.
8. Livdelzi (seladelpar) prescribing information. Gilead Sciences, Inc., Foster City, CA. Revised August 2024.
9. Hirschfield GM, Shiffman ML, Gulamhusien A, et al. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. *Hepatology*. 2023;78:397-415. DOI: 10.1097/HEP.0000000000000395
10. Hirschfield GM, Bowles CL, Mayo MJ, et al. A Phase 3 trial of seladelpar in primary biliary cholangitis. *N Engl J Med*. 2024;390(9):783-794. DOI: 10.1056/NEJMoa2312100
11. Mayo MJ, Vierling JM, Bowlus CL, et al. Open-label, clinical trial extension: two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. *Aliment Pharmacol Ther*. 2024;59:186-200.DOI: 10.1111/apt.17755
12. Rezdiffra (resmetirom) prescribing information. UPM Pharmaceuticals. Bristol, TN. Revised March 2024.
13. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology (Baltimore, Md)*. 2016;64(1):73-84.
14. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology (Baltimore, Md)*. 2018;67(1):328-357.
15. Park S, Lee S, Kim Y, et al. Altered Risk for Cardiovascular Events With Changes in the Metabolic Syndrome Status: A Nationwide Population-Based Study of Approximately 10 Million Persons. *Ann Intern Med*. 2019.
16. Adams TD, Davidson LE, Litwin SE, et al. Weight and Metabolic Outcomes 12 Years after Gastric Bypass. *The New England journal of medicine*. 2017;377(12):1143-1155.

History

Date	Comments
04/01/20	New policy, approved March 10, 2020. Criteria for Ocaliva (obeticholic acid) for primary biliary cholangitis added.
01/01/22	Annual Review, approved December 2, 2021. Updated Ocaliva criteria to restrict use to patients without cirrhosis or with compensated cirrhosis who do not have evidence of portal hypertension.
11/01/22	Annual Review, approved October 24, 2022. No changes to policy statement. Changed the wording from "patient" to "individual" throughout the policy for standardization.
09/01/23	Annual Review, approved August 21, 2023. No changes to the policy statements.
09/01/24	Annual Review, approved August 13, 2024. Added Iqirvo (elafibranor) coverage criteria. Updated Ocaliva (obeticholic acid) coverage criteria to include a prescriber



Date	Comments
	requirement, a requirement that Ocaliva will not be used in combination with Iqirvo, and a quantity limit.
02/01/25	Annual Review, approved January 14, 2025. Added Livdelzi (seladelpar) coverage criteria for the treatment of PBC. Updated Iqirvo and Ocaliva criteria to exclude combination use with Livdelzi. Rezdiffra (resmetirom) moved from Policy 5.01.605 Medical Necessity Criteria for Pharmacy Edits to Policy 5.01.615 Pharmacologic Treatment of Chronic Non-Infectious Liver Diseases with no changes to the coverage criteria. Clarified that the medications listed in this policy are subject to the product's FDA dosage and administration prescribing information. Clarified that non-formulary exception review authorizations for all drugs listed in this policy may be approved up to 12 months.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2025 Premera All Rights Reserved.

Scope: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.

